DEPARTMENT OF EDUCATION

34 CFR Part 300

[Docket ID ED–2020–OSERS–0191]

Proposed Guidance; Questions and Answers on Serving Children With Disabilities Placed by Their Parents in Private Schools

Correction

In proposed rule document 2020–27872 appearing on pages 82994–82995 in the issue of Monday, December 21, 2020, make the following correction:

(1) On page 82994, in the third column, in the **DATES** section, change ''January 20, 2021'' to read ''January 21, 2021.''

[FR Doc. C1–2020–27872 Filed 1–12–21; 8:45 am]

BILLING CODE 1301–00–D

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA–R07–OAR–2020–0620; FRL–10017–81–Region 7]

Air Plan Approval; Missouri; Removal of Control of Emissions From Solvent Cleanup Operations

Correction

In proposed rule document 2020–28121 appearing on pages 82995 through 82998 in the issue of Monday, December 21, 2020, make the following correction:

(1) On page 82995, in the second column, in the **DATES** section, change ''January 20, 2021'' to read ''January 21, 2021.''

[FR Doc. C1–2020–28121 Filed 1–12–21; 8:45 am]

BILLING CODE 1301–00–D

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 180

[EPA–HQ–OPP–2020–0053; FRL–10016–93]

Receipt of Several Pesticide Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities (October 2020)

Correction

In proposed rule document 2020–28117 appearing on pages 82998 through 83000 in the issue of Monday, December 21, 2020, make the following correction:

(1) On page 82998, in the second column, in the **DATES** section, change ''January 20, 2021'' to read ''January 21, 2021.''

[FR Doc. C1–2020–28117 Filed 1–12–21; 8:45 am]

BILLING CODE 1301–00–D

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

45 CFR Parts 46 and 75

RIN 0991–AC15

Establishment of Safeguards and Program Integrity Requirements for Health and Human Services-Funded Extramural Research Involving Human Fetal Tissue

AGENCY: Office of the Secretary, Department of Health and Human Services.

ACTION: Notice of proposed rulemaking.

SUMMARY: This is a notice of proposed rulemaking to amend certain regulatory provisions in order to adopt or strengthen safeguards and program integrity requirements applicable to extramural research involving human fetal tissue from elective abortions.

DATES: Comments must be submitted on or before February 12, 2021.

ADDRESSES: Comments must be identified by RIN 0991–AC15. Because of staff and resource limitations, comments must be submitted electronically to *www.regulations.gov.* Follow the ''Submit a comment'' instructions.

Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including personally identifiable or confidential business information that is included in a comment. Before or after the close of the comment period, the Department of Health and Human Services will post all comments that were received before the end of the comment period on *www.regulations.gov.* Follow the search instructions on that website to view the public comments.

FOR FURTHER INFORMATION CONTACT: Daniel Barry at *daniel.barry@hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Introduction

In September 2018, the Department of Health and Human Services (HHS) terminated a contract that provided human fetal tissue from elective abortions to the Food and Drug Administration (FDA) for the development of testing protocols. HHS terminated the contract because it was not sufficiently assured that the contract included the appropriate protections applicable to fetal tissue research or met all other procurement requirements. HHS subsequently initiated a comprehensive review of all HHS research involving human fetal tissue from elective abortions to ensure consistency with the statutes and regulations governing such research and to ensure the adequacy of procedures and oversight in light of the serious regulatory, moral, and ethical considerations involved.

Promoting the dignity of human life from conception to natural death is one of the top priorities of President Trump's administration. The audit and review informed the policy process that led to the administration's decision, announced June 5, 2019,[1] to discontinue National Institutes of Health (NIH) intramural research—research conducted within NIH by NIH researchers—involving the use of human fetal tissue from elective abortion. With respect to extramural research (research conducted outside of, but funded by, NIH, *e.g.,* at universities), the administration announced that, for new extramural research grant applications or current research projects in the competitive renewal process (generally every five years) that propose to use fetal tissue from elective abortions and that are recommended for potential funding through NIH's two-level external scientific review process, an ethics advisory board will be convened to review the research proposal and recommend whether, in light of the ethical considerations, NIH should fund the research project—pursuant to a law passed by Congress (42 U.S.C 289a–1).

In the same policy statement, HHS announced that it would also undertake changes to its regulations and to NIH grants policy to adopt or strengthen safeguards and program integrity requirements applicable to extramural research involving human fetal tissue from elective abortions.[2] In this notice of proposed rulemaking, HHS proposes revisions to its Human Research Subjects Protection Regulations (45 CFR part 46, subpart B, Additional Protections for Pregnant Women, Human Fetuses, and Neonates) and its

[1] *See* Statement from the Department of Health and Human Services, June 5, 2019, available at *https://www.hhs.gov/about/news/2019/06/05/statement-from-the-department-of-health-and-human-services.html.*

[2] *See* Statement from the Department of Health and Human Services, June 5, 2019, available at *https://www.hhs.gov/about/news/2019/06/05/statement-from-the-department-of-health-and-human-services.html.*